Literature DB >> 18652797

Depression in the medically ill: diagnostic and therapeutic implications.

Meera Narasimhan1, Jeffrey D Raynor, Ashley Blackmon Jones.   

Abstract

Depression and medical comorbidities lead to increased morbidity and mortality and have been associated with higher health care costs. Depressive disorders can adversely impact the course of medical illnesses, whereas medical illnesses can serve as a risk factor for future depressive disorders. This interplay has spurred some interesting exploratory research to understand the common pathophysiology and neurobiologic substrates that may explain the bidirectional relationship between the two disorders. There is a paucity of well-designed, randomized, controlled trials to address some of the treatment-related prognostic issues in this population. However, more recent studies have focused on diagnostic and treatment implications with various available pharmacologic and psychotherapeutic modalities. Early identification and appropriate treatment of depression in the medically ill can positively influence medical outcomes and quality of life. Collaborative care models integrating mental health and primary care providers, combined with patient preference, are found to be cost-effective and may result in better response to depression treatment.

Entities:  

Mesh:

Year:  2008        PMID: 18652797     DOI: 10.1007/s11920-008-0044-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  70 in total

1.  STAR*D: what have we learned?

Authors:  A John Rush
Journal:  Am J Psychiatry       Date:  2007-02       Impact factor: 18.112

2.  Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial.

Authors:  J G Rabkin; G J Wagner; R Rabkin
Journal:  Am J Psychiatry       Date:  1999-01       Impact factor: 18.112

3.  Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.

Authors:  François Lespérance; Nancy Frasure-Smith; Diana Koszycki; Marc-André Laliberté; Louis T van Zyl; Brian Baker; John Robert Swenson; Kayhan Ghatavi; Beth L Abramson; Paul Dorian; Marie-Claude Guertin
Journal:  JAMA       Date:  2007-01-24       Impact factor: 56.272

4.  Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study.

Authors:  I Connerney; P A Shapiro; J S McLaughlin; E Bagiella; R P Sloan
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

5.  Association of depression and diabetes complications: a meta-analysis.

Authors:  M de Groot; R Anderson; K E Freedland; R E Clouse; P J Lustman
Journal:  Psychosom Med       Date:  2001 Jul-Aug       Impact factor: 4.312

6.  Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic.

Authors:  D O Perkins; R A Stern; R N Golden; C Murphy; D Naftolowitz; D L Evans
Journal:  Am J Psychiatry       Date:  1994-02       Impact factor: 18.112

7.  Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study.

Authors:  Renerio Fraguas; Dan V Iosifescu; Jonathan Alpert; Stephen R Wisniewski; Jennifer L Barkin; Madhukar H Trivedi; A John Rush; Maurizio Fava
Journal:  Psychosomatics       Date:  2007 Sep-Oct       Impact factor: 2.386

8.  Depression and functional status as predictors of death among cancer patients.

Authors:  Manfred Stommel; Barbara A Given; Charles W Given
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

9.  Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review.

Authors:  D A Fishbain; R Cutler; H L Rosomoff; R S Rosomoff
Journal:  Pain Med       Date:  2000-12       Impact factor: 3.750

10.  Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production.

Authors:  S W Cole; Y D Korin; J L Fahey; J A Zack
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

View more
  3 in total

Review 1.  If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.

Authors:  K Ryan Connolly; Michael E Thase
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

Review 2.  Vilazodone: in major depressive disorder.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

3.  Patient preference in psychological treatment and associations with self-reported outcome: national cross-sectional survey in England and Wales.

Authors:  Ryan Williams; Lorna Farquharson; Lucy Palmer; Paul Bassett; Jeremy Clarke; David M Clark; Mike J Crawford
Journal:  BMC Psychiatry       Date:  2016-01-15       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.